Exor Valuation
Is 0RKY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
6/6Valuation Score 6/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0RKY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0RKY (€94) is trading below our estimate of fair value (€281.98)
Significantly Below Fair Value: 0RKY is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0RKY?
Key metric: As 0RKY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0RKY's PE Ratio? | |
|---|---|
| PE Ratio | 1.2x |
| Earnings | €16.73b |
| Market Cap | €20.29b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.6x |
| Enterprise Value/EBITDA | 1.3x |
| PEG Ratio | -0.01x |
Price to Earnings Ratio vs Peers
How does 0RKY's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.4x | ||
WISE Wise | 19.9x | -7.9% | UK£8.6b |
KSPI Kaspi.kz | 12.2x | 17.0% | US$22.8b |
III 3i Group | 7.9x | 17.7% | UK£33.3b |
HL. Hargreaves Lansdown | 17.6x | 1.6% | UK£5.2b |
0RKY Exor | 1.2x | -87.4% | €20.3b |
Price-To-Earnings vs Peers: 0RKY is good value based on its Price-To-Earnings Ratio (1.2x) compared to the peer average (14.4x).
Price to Earnings Ratio vs Industry
How does 0RKY's PE Ratio compare vs other companies in the GB Diversified Financial Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 14.2x | 10.0% | |
0RKY Exor | 1.2x | -87.4% | US$21.36b |
NBS Nationwide Building Society | 0.9x | n/a | US$1.52b |
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 14.2x | 10.0% | |
0RKY Exor | 1.2x | -87.4% | US$21.36b |
Price-To-Earnings vs Industry: 0RKY is good value based on its Price-To-Earnings Ratio (1.2x) compared to the UK Diversified Financial industry average (14.2x).
Price to Earnings Ratio vs Fair Ratio
What is 0RKY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 1.2x |
| Fair PE Ratio | 5x |
Price-To-Earnings vs Fair Ratio: 0RKY is good value based on its Price-To-Earnings Ratio (1.2x) compared to the estimated Fair Price-To-Earnings Ratio (5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €94.00 | €123.86 +31.8% | 4.4% | €130.00 | €113.00 | n/a | 7 |
| Nov ’25 | €97.95 | €123.86 +26.4% | 4.4% | €130.00 | €113.00 | n/a | 7 |
| Oct ’25 | €96.96 | €118.00 +21.7% | 13.6% | €130.00 | €84.00 | n/a | 6 |
| Sep ’25 | €100.97 | €118.00 +16.9% | 13.7% | €130.00 | €84.00 | n/a | 6 |
| Aug ’25 | €94.12 | €118.00 +25.4% | 13.7% | €130.00 | €84.00 | n/a | 6 |
| Jul ’25 | €98.30 | €117.43 +19.5% | 12.8% | €130.00 | €84.00 | n/a | 7 |
| Jun ’25 | €102.90 | €117.43 +14.1% | 12.8% | €130.00 | €84.00 | n/a | 7 |
| May ’25 | €102.70 | €123.00 +19.8% | 5.6% | €130.00 | €114.00 | n/a | 6 |
| Apr ’25 | €102.71 | €111.60 +8.7% | 4.1% | €115.00 | €103.00 | n/a | 5 |
| Mar ’25 | €100.53 | €107.00 +6.4% | 10.4% | €115.00 | €84.00 | n/a | 6 |
| Feb ’25 | €91.71 | €107.00 +16.7% | 10.4% | €115.00 | €84.00 | n/a | 6 |
| Jan ’25 | €90.25 | €106.33 +17.8% | 10.7% | €115.00 | €84.00 | n/a | 6 |
| Dec ’24 | €89.93 | €105.50 +17.3% | 10.4% | €115.00 | €84.00 | n/a | 6 |
| Nov ’24 | €81.75 | €102.40 +25.3% | 10.4% | €115.00 | €84.00 | €97.95 | 5 |
| Oct ’24 | €84.41 | €100.80 +19.4% | 9.1% | €110.00 | €84.00 | €96.96 | 5 |
| Sep ’24 | €81.23 | €99.25 +22.2% | 9.1% | €107.00 | €84.00 | €100.97 | 4 |
| Aug ’24 | €84.20 | €99.25 +17.9% | 9.1% | €107.00 | €84.00 | €94.12 | 4 |
| Jul ’24 | €81.87 | €99.25 +21.2% | 9.1% | €107.00 | €84.00 | €98.30 | 4 |
| Jun ’24 | €78.23 | €101.00 +29.1% | 8.7% | €108.00 | €84.00 | €102.90 | 5 |
| May ’24 | €73.75 | €98.00 +32.9% | 9.4% | €108.00 | €84.00 | €102.70 | 4 |
| Apr ’24 | €75.67 | €96.00 +26.9% | 7.7% | €103.00 | €84.00 | €102.71 | 4 |
| Mar ’24 | €78.29 | €96.00 +22.6% | 7.7% | €103.00 | €84.00 | €100.53 | 4 |
| Feb ’24 | €73.13 | €96.00 +31.3% | 7.7% | €103.00 | €84.00 | €91.71 | 4 |
| Jan ’24 | €68.61 | €96.00 +39.9% | 7.7% | €103.00 | €84.00 | €90.25 | 4 |
| Dec ’23 | €76.41 | €93.75 +22.7% | 8.9% | €103.00 | €84.00 | €89.93 | 4 |
| Nov ’23 | €68.07 | €93.00 +36.6% | 13.7% | €103.00 | €75.00 | €81.75 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
BFF Bank
€1.7b
Provides financial services to suppliers of the national health system and public administration sector in Italy, Croatia, the Czech Republic, France, Greece, Poland, Portugal, the Slovak Republic, and Spain.
0RON
€8.82
7D
1.3%
1Y
-10.9%
Man Group
UK£2.4b
Man Group Limited is a publicly owned investment manager.
EMGL
UK£2.11
7D
2.6%
1Y
-3.4%
illimity Bank
€264.8m
Provides private banking, and investment and trading services in Italy.
0A3J
€3.07
7D
-18.1%
1Y
-44.9%